To study the effect of Unani medicine in urticaria

A Single Blinded Clinical Trial Shara (Urticaria) With Unani Polyherbal Formulation - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059929

Enrollment

Registered

2023-11-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Unani Polyherbal Formulation: 5 mg PO , TID, After meals, for 45 days Ointment for Local Application Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 - 55 years 2. Patients of either sex 3. Mild to severe pruiritis 4. Skin eruptions, itching and burning sensation

Exclusion criteria

Exclusion criteria: Patients with 1. Angioedema without wheals 2. Urticarial vasculitis 3. Severe acute/chronic urticaria 4. Pregnant and lactating women 5. Uncontrolled Hypertension and DM 6. SLE 7. Anaphylactic shock 8. Co morbid conditions like cardiac, respiratory, renal disorders and Carcinoma

Design outcomes

Primary

Measure	Time frame
Outcome depends on Urticria Activity Score (UAS)Timepoint: Symptoms to be reviewed within 45 days	—

Secondary

Measure	Time frame
Relief in symptoms such as itching, rednessTimepoint: Symptoms will be assessed within 45 days	—

Countries

India

Contacts

Public ContactDr Juveria Parveen

Government Nizamia Tibbi College and General Hospital

dr.n.narasimha@gmail.com9866985269

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026